Second-Year Visual Acuity Outcomes of nAMD Patients Treated With Aflibercept: Data Analysis From the UK Aflibercept Users Group

Eye- United Kingdom

doi 10.1038/eye.2017.108

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration in Patients Aged 90 Years or Older: 2-Year Visual Acuity Outcomes

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2018English

Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration With Good Visual Acuity: 2-Year Results of a Prospective Study

Clinical Ophthalmology
Ophthalmology
2018English

A Retrospective Analysis of the Effect of Subretinal Hyper-Reflective Material and Other Morphological Features of Neovascular Age-Related Macular Degeneration on Visual Acuity Outcomes in Eyes Treated With Intravitreal Aflibercept Over One Year

Vision (Switzerland)
OphthalmologyCognitive NeuroscienceOptometrySensory SystemsCell Biology
2018English

Incidence and Risk of Proteinuria With Aflibercept in Cancer Patients: A Meta-Analysis

PLoS ONE
Multidisciplinary
2014English

A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients With Treatment Resistant Neovascular Age-Related Macular Degeneration Following Switching to Treatment With Aflibercept

Journal of Ophthalmology
Ophthalmology
2016English

Pss5 - Vision-Related Quality of Life in Patients With Diabetic Macular Edema Treated With Intravitreal Aflibercept: The Aqua Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Comment On: ‘One-Year Real-World Outcomes in Patients Receiving Fixed-Dosing Aflibercept for Neovascular Age-Related Macular Degeneration’

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2017English

A Phase I Study of Intravenous Aflibercept With FOLFIRI in Japanese Patients With Previously Treated Metastatic Colorectal Cancer

Investigational New Drugs
OncologyPharmacology
2012English

Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data From an Observational Study

Ophthalmology
Ophthalmology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy